Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Añadir filtros








Intervalo de año
1.
Arch. endocrinol. metab. (Online) ; 62(3): 366-369, May-June 2018. graf
Artículo en Inglés | LILACS | ID: biblio-1038490

RESUMEN

ABSTRACT Objective: Graves' ophthalmopathy (GO) is an autoimmune disease that leads to ocular proptosis caused by fat accumulation and inflammation, and the main treatment is corticosteroid therapy. Retinoid acid receptor-alpha (RARα) seems to be associated with inflammation and adipocyte differentiation. This study aimed to assess the effect of glucocorticoid treatment on orbital fibroblasts of GO patient treated or not with different glucocorticoid doses. Materials and methods: Orbital fibroblasts collected during orbital decompression of a female patient with moderately severe/severe GO were cultivated and treated with 10 nM and 100 nM dexamethasone (Dex). rRARα gene expression in the treated and untreated cells was then compared. Results: Fibroblast RARα expression was not affected by 100 nM Dex. On the other hand, RARα expression was 24% lower in cells treated with 10 nM Dex (p < 0.05). Conclusions: Orbital fibroblasts from a GO patient expressed the RARα gene, which was unaffected by higher, but decreased with lower doses of glucocorticoid.


Asunto(s)
Humanos , Órbita/efectos de los fármacos , Dexametasona/administración & dosificación , Expresión Génica/efectos de los fármacos , Oftalmopatía de Graves/tratamiento farmacológico , Fibroblastos/química , Glucocorticoides/administración & dosificación , Órbita/patología , Índice de Severidad de la Enfermedad , Oftalmopatía de Graves/patología , Fibroblastos/efectos de los fármacos , Receptor alfa de Ácido Retinoico/efectos de los fármacos , Receptor alfa de Ácido Retinoico/genética
2.
Arch. endocrinol. metab. (Online) ; 59(3): 273-276, 06/2015. graf
Artículo en Inglés | LILACS | ID: lil-751322

RESUMEN

Graves’ ophthalmopathy (GO) is one of the most severe clinical manifestations of Graves’ disease (GD), and its treatment might involve high-dose glucocorticoid therapy. The higher incidence of GO among females, and the reported association between polymorphisms of estrogen receptor (ER) and GD susceptibility have led us to question the role of estrogen and its receptor in GO pathogenesis. We, thus, assessed estrogen receptor-alpha (ERA) gene expression in cultures of orbital fibroblasts from a patient with GO before (controls) and after treatment with 10 nM and 100 nM dexamethasone (DEX). Orbital fibroblasts showed ERA gene expression. In the cells treated with 10 nM and 100 nM DEX, ERA gene expression was, respectively, 85% higher and 74% lower, than in the control group. We concluded that ERA gene expression is found in the orbital fibroblasts of patient with GO, which may be affected by glucocorticoids in a dose-related manner. Arch Endocrinol Metab. 2015;59(3):273-6.


Asunto(s)
Humanos , Adenocarcinoma/patología , Esófago de Barrett/patología , Carcinoma in Situ/patología , Neoplasias Esofágicas/patología , Unión Esofagogástrica/patología , Membrana Mucosa/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA